Sigyn Therapeutics Expands Cardiovascular Disease Study to Target Lipoprotein Reduction
Sigyn Therapeutics plans a clinical feasibility study of its blood purification technology that could address cardiovascular disease in high-risk patients while potentially extending lives of end-stage renal disease patients and generating significant economic impact.
Sigyn Therapeutics, Inc. announced plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease subjects. Cardiovascular disease remains the leading cause of death globally according to the World Health Organization, making this development particularly significant for patient care and treatment accessibility.
The company's blood purification technology represents a novel approach to cardiovascular disease management. Sigyn Therapy™ is designed for use on dialysis machines located in hospitals and clinics worldwide, targeting both inflammatory molecules that promote cardiovascular disease progression and cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other major adverse cardiovascular events.
Based on insights from pre-clinical in vitro studies, the company is expanding its feasibility study protocol to quantify lipoprotein reduction. This expansion could position Sigyn Therapy™ as a broader-spectrum treatment approach. The successful completion of the feasibility study would set the stage for a pivotal efficacy study necessary to pursue potential market clearance.
The technology operates similarly to established lipoprotein apheresis treatments, which have demonstrated 55% to 98% reductions in major adverse cardiovascular events in clinical studies. However, current lipoprotein apheresis access in the United States is limited to fewer than 60 specialized centers, while Sigyn Therapy™ can be deployed on dialysis machines located in approximately 7,500 U.S. dialysis clinics according to company information available at https://www.sigyntherapeutics.com.
Jim Joyce, Sigyn Therapeutics' CEO, emphasized the potential impact: "Targeting the bloodstream reduction of Lp(a) and LDL-C while simultaneously suppressing dialysis-induced endotoxemia and inflammation introduces a broad-spectrum strategy to extend ESRD patient lives by addressing multiple core drivers of cardiovascular disease."
The economic implications are substantial. The U.S. dialysis industry generates approximately $34 billion in annual revenues from administering roughly 85 million dialysis treatments to more than 550,000 end-stage renal disease patients. Most ESRD patients die from cardiovascular disease without effective therapeutic intervention. Extending ESRD patient lives by just one month could increase industry revenues by approximately $2.8 billion, primarily benefiting market leaders Fresenius Medical Care and Davita, Inc., who control 75% of the U.S. dialysis market.
This development represents a potential shift in cardiovascular disease treatment paradigms, particularly for high-risk patients with concurrent conditions. The ability to administer the therapy during regularly scheduled dialysis treatments could significantly improve treatment accessibility and patient compliance compared to existing limited-access apheresis treatments.